Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Transcode Therapeutics Inc (RNAZ)

7 + Investors. Track Smart Money conviction in RNAZ. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +2
Streak
1Q ▲
Buyers last Q
67%

Smart Money Signals — RNAZ

Based on 7 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 3Q
For 1 consecutive quarter, more hedge funds added RNAZ than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
7 hedge funds hold RNAZ right now — the highest count in 1.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🟢

More buyers than sellers — 67% buying

6 buying3 selling
Last quarter: 6 funds were net buyers (4 opened a brand new position + 2 added to an existing one). Only 3 were sellers (1 trimmed + 2 sold completely). A clear majority buying is a strong confirmation signal.
➡️

Steady new buyers — ~4 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 4 → 1 → 4. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔄

Mostly new holders — 71% entered in last year

0% conviction (2yr+) 29% medium 71% new
Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Value +905% but shares only +697% — price-driven

Value
+904%
Shares
+696%
Last quarter: the total dollar value of institutional holdings rose +905%, but actual share count only changed +697%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📊

Peak discovery — momentum slowing

4 → 1 → 4 new funds/Q
New funds entering each quarter: 4 → 1 → 4. RNAZ is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🌱

Early stage — 100% of holders entered in last year

0% veterans 0% 1-2yr 100% new
Of 7 current holders: 7 (100%) entered in the past year, only 0 (0%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
🏆

Elite ownership — 68% AUM from top-100 funds

68% from top-100 AUM funds
3 of 7 holders are among the 100 largest funds by AUM, controlling 68% of total institutional value in RNAZ. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.8
out of 10
Moderate Exit Risk
Exit risk score 4.8/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — RNAZ

In 2026 Q1, 6 hedge funds were net buyers of RNAZ (4 opened a new position, 2 added to an existing one), while 3 reduced or exited (1 trimmed, 2 sold completely) — a 67% buyer ratio, indicating clear institutional accumulation. 68% of total institutional value in RNAZ is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +2 funds (more new holders than closures). Total institutional holders: 7.

Hedge Fund Ownership: RNAZ

How many hedge funds hold RNAZ — quarterly history vs. share price
Quarterly hedge fund ownership of RNAZ vs. share price

Market Analysis: RNAZ

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: RNAZ

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Transcode Therapeutics Inc (RNAZ) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much RNAZ has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 82d ago
RNAZ
nan%
XLV
+1.9%

RNAZ outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 37d ago
RNAZ
nan%
XLV
+3.0%

Since the filing became public, RNAZ outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

2 top-rated funds 0 high-conviction
Consensus
2.1
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: RNAZ
7 + Investors

Track Smart Money conviction in RNAZ. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 7 5 40.0%
13F Shares 31K 4K 696.93%
Total Value $266K $26K 904.6%
New Positions 4 1 +3
Increased Positions 2 1 +1
Closed Positions 2 3 -1
Reduced Positions 1 0 +1
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: RNAZ

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

7 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RNAZ. Verified SEC 13F-HR filings.

QUARTER:
Top 6 RNAZ holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Tower Research Capital LLC (TRC) 0.00% 228 $2K
2 UBS Group AG 0.00% 8,295 $71K
3 Vanguard Fiduciary Trust Co 0.00% 2,982 $26K
4 SBI Securities Co., Ltd. 0.00% 12
5 Vanguard Capital Management LLC 0.00% 6,545 $56K
6 Wells Fargo & Company/Mn 0.00% 55
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Transcode Therapeutics Inc (RNAZ)

What does the Smart Money Trend signal show for RNAZ?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added RNAZ than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RNAZ?

More buyers than sellers — 67% buying: Last quarter: 6 funds were net buyers (4 opened a brand new position + 2 added to an existing one). Only 3 were sellers (1 trimmed + 2 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for RNAZ holders?

Elite ownership — 68% AUM from top-100 funds: 3 of 7 holders are among the 100 largest funds by AUM, controlling 68% of total institutional value in RNAZ. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held RNAZ?

Mostly new holders — 71% entered in last year: Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Transcode Therapeutics Inc (RNAZ) following the 2026 Q1 hedge fund 13F filings?

As of today, RNAZ has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.0% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), RNAZ has gained nan% vs +1.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →